Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

Trial Profile

Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Dasatinib (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 19 Dec 2016 Primary endpoint (Overall survival) has not been met, according to results published in the Annals of Oncology journal.
    • 19 Dec 2016 Results of this study, published in the Annals of Oncology journal.
    • 12 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top